ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for default Registrieren Sie sich kostenlos, um Echtzeitkurse, interaktive Charts, Live-Optionsfluss und mehr zu erhalten.

QNCX Quince Therapeutics Inc

0,71
0,0121 (1,73%)
15 Jun 2024 - Geschlossen
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Quince Therapeutics Inc QNCX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,0121 1,73% 0,71 06:00:04
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
0,70 0,6979 0,72 0,71 0,6979
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
08.6.202403:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.6.202403:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.6.202402:59EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06.6.202423:17EDGAR2Form 8-K - Current report
05.6.202420:37EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.6.202413:00BWQuince Therapeutics Receives U.S. FDA Fast Track Designation..
13.5.202413:30EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
13.5.202413:00BWQuince Therapeutics Provides Business Update and Reports..
06.5.202422:05BWQuince Therapeutics to Present at The Citizens JMP Life..
01.4.202413:00BWQuince Therapeutics Provides Business Update and Reports..
22.2.202413:00BWQuince Therapeutics Launches Scientific Advisory Board
15.2.202422:00EDGAR2Form 8-K - Current report
15.2.202413:00BWQuince Therapeutics Appoints Former Reata Pharmaceuticals..
07.2.202422:05BWQuince Therapeutics to Present at Oppenheimer 34th Annual..
02.2.202423:53EDGAR2Form 4 - Statement of changes in beneficial ownership of..
05.1.202422:01EDGAR2Form 8-K/A - Current report: [Amend]
04.1.202422:05BWQuince Therapeutics to Participate at Investor Events in..
03.1.202422:02EDGAR2Form 8-K - Current report
22.12.202322:08EDGAR2Form 8-K - Current report
15.12.202300:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
08.12.202322:06EDGAR2Form 8-K - Current report
08.12.202300:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
01.12.202319:38EDGAR2Form 4 - Statement of changes in beneficial ownership of..
26.10.202323:54EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25.10.202301:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25.10.202301:34EDGAR2Form 3 - Initial statement of beneficial ownership of..
23.10.202322:05EDGAR2Form 8-K - Current report
23.10.202313:00BWQuince Therapeutics Completes Acquisition of EryDel S.p.A.
28.9.202322:53DJNQuince Therapeutics to Advance Study of EryDex as FDA Lifts..
28.9.202322:05BWU.S. FDA Partial Clinical Hold Lifted on IND for EryDel’s..
06.9.202313:18EDGAR2Form 8-K - Current report
06.9.202313:00BWQuince Therapeutics Appoints Dr. Charles S. Ryan as..
01.9.202300:42EDGAR2Form 4 - Statement of changes in beneficial ownership of..
18.8.202300:08EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10.8.202323:05EDGAR2Form 8-K - Current report
10.8.202322:05BWQuince Therapeutics to Present at Sidoti Virtual Investor..
10.8.202300:21EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10.8.202300:18EDGAR2Form 4 - Statement of changes in beneficial ownership of..
03.8.202322:20EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
24.7.202323:56BWQuince Therapeutics rileva EryDel SpA e il suo asset di fase..
24.7.202313:16EDGAR2Form 8-K - Current report
24.7.202313:00BWQuince Therapeutics to Acquire EryDel SpA and its Phase 3..

Kürzlich von Ihnen besucht